Tuesday, May 12, 2026
← Back to archivePolicy
Policy•STAT News•May 12, 2026
Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
background ▾
- •China's biopharmaceutical licensing deal value increased 15-fold in five years ($9B to $137B), with U.S. pharma executives actively participating in this shift
- •An estimated 60-90% of U.S. generic medications have active ingredients originating in China, creating critical supply chain vulnerability that the FDA does not formally track
- •Watch for potential regulatory or legislative responses addressing pharmaceutical supply chain sovereignty and mandatory country-of-origin disclosure requirements
Policy•Fierce Pharma•May 11, 2026
Partner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer
background ▾
- •Bizengri becomes the third approved indication under CNPV pilot, demonstrating program's expedited review capacity (two-day turnaround vs. standard 10-12 months), though based on limited midphase data (n=19 evaluable patients with 36.8% response rate)
- •CNPV program faces intensifying political and regulatory scrutiny regarding corruption vulnerabilities, sponsor favoritism, and potential erosion of FDA review standards; FDA has scheduled June 4 public hearing to address eligibility, selection processes, and implementation procedures
- •Watch the June 4 FDA public hearing outcome and any potential program modifications; monitor whether Bizengri's limited efficacy data (median response duration 2.8-12.9 months) translates to real-world clinical benefit and payer acceptance in this ultra-rare NRG1+ cholangiocarcinoma subset (<1% of cases)
Partner TherapeuticsMerusFDABizengri
→ Read original articlePolicy•STAT News•May 12, 2026
PCOS’s new name is PMOS, a small letter change that required a big scientific process
background ▾
- •PCOS officially renamed to PMOS to reflect the condition's true metabolic and endocrine nature rather than misleading focus on ovarian cysts, which should improve diagnostic accuracy for the estimated 70% of affected individuals currently undiagnosed.
- •The renaming process involved the most extensive disease-renaming effort in history, with nearly 22,000 stakeholders surveyed across three major rounds (2017, 2023, 2025) and global workshop testing, indicating strong industry consensus on the need for change.
- •Key uncertainty remains regarding male presentations of the syndrome—dissenting advocates argue the new name's retention of "ovarian" precludes recognition of sex-specific variants, a concern likely to drive continued debate in endocrinology and clinical practice communities.
Policy•STAT News•May 12, 2026
6 takeaways from STAT’s investigation into the U.S. alcohol epidemic
background ▾
- •Alcohol kills 178,000 Americans annually yet receives minimal attention from policymakers and federal agencies compared to opioid crisis despite being deadliest drug.
Policy•KFF•May 11, 2026
5 Key Facts on Adolescent Mental Health and Substance Use Disorders
background ▾
- •Recent policy rollbacks are disrupting school-based mental health funding and threatening coverage expansion via Medicaid, which covers 40% of children and teens, despite evidence that 2024 prevalence rates show 15% with depression and 19% with anxiety
- •The 988 crisis hotline—recently linked to decreased adolescent suicide mortality—faces flat funding in 2027 and has already lost specialized support for LGBTQ youth, a higher-risk population
- •Monitor implementation of proposed SAMHSA restructuring and Medicaid changes for impact on behavioral health access; track whether school-based mental health provider retention becomes critical shortage
Market Access
Market Access•Fierce Pharma•May 12, 2026
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
background ▾
- •CSL's $5B impairment on Vifor acquisition represents a material acknowledgment that the 2022 deal has underperformed significantly relative to acquisition thesis
- •Revenue miss of $600M combined with R&D pipeline gaps suggests both commercial execution problems and innovation challenges in the combined entity
- •Watch for leadership changes, restructuring announcements, and potential strategic review of the Vifor integration or standalone viability
CSL LimitedVifor Pharma
→ Read original articleMarket Access•Fierce Biotech•May 11, 2026
Novo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech
background ▾
- •Novo successfully rehomed its clinical-stage Parkinson's cell therapy after October 2023 cell therapy exit, securing milestone payments and royalties while making an equity investment in Cellular Intelligence
- •STEM-PD is positioned to differentiate via AI-driven cell optimization targeting manufacturing scalability and cost issues that have plagued cell replacement therapies, with phase 2 expected by end of 2024
- •Competitive intensity in Parkinson's cell therapy is rising with Aspen Neuroscience advancing autologous approach toward phase 3; watch phase 2 STEM-PD data and manufacturing validation as proof-of-concept for Cellular Intelligence's platform
Novo NordiskCellular IntelligenceAspen NeuroscienceSTEM-PD
→ Read original articleMarket Access•KFF•May 12, 2026
When Minutes Matter, What Is AI’s Role?
background ▾
- •Aidoc operates the most widely deployed FDA-cleared clinical AI platform in healthcare with 32 total clearances, 1,600+ hospital installations, and 70 million annual cases analyzed
- •The company's AI prioritizes time-sensitive findings (hemorrhages, PE, aortic dissection) by flagging critical cases first, addressing workflow bottlenecks in emergency departments where diagnostic order can affect patient outcomes
- •Key uncertainties remain about whether regulatory validation translates to scaled patient outcome improvement given structural barriers in reimbursement, clinical integration, and liability frameworks
Aidoc
→ Read original articleMarket Access•Fierce Pharma•May 12, 2026
OVID Health hires Edelman alum Davide Scalenghe to boost its international footprint
background ▾
- •OVID Health is strategically investing in international market access capabilities by recruiting experienced communications talent
OVID HealthEdelman
→ Read original articleMarket Access•Fierce Pharma•May 12, 2026
Eli Lilly shoots for health in new Caitlin Clark ad campaign
background ▾
- •Eli Lilly is leveraging celebrity athlete endorsements (Caitlin Clark) in a health-focused corporate branding campaign, signaling a shift from traditional direct-to-consumer pharmaceutical advertising
Eli Lilly
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•May 11, 2026
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
background ▾
- •INBRX-106 + Keytruda achieved 44% ORR versus 21.4% for Keytruda alone in high PD-L1 HNSCC, with superior depth of response and complete responses only in the combination arm—potentially addressing the historical underperformance of OX40 agonists.
- •Phase 3 initiation planned for Q3 2024 with progression-free survival data expected Q4 2024; expansion roadmap includes perioperative NSCLC, frontline metastatic NSCLC, and combination strategies with vaccines, T-cell engagers, and CAR-Ts.
- •Acquisition dynamics: Merck acquisition could shield Keytruda from biosimilar erosion by shifting treatment paradigm to combination therapy; pipeline valued at ~$9 billion to potential buyers depending on further clinical validation.
Inhibrx BiosciencesMerck & Co.Merck KGaAINBRX-106Keytruda (pembrolizumab)
→ Read original articleClinical Trials•Fierce Biotech•May 12, 2026
Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled
background ▾
- •ETD001 is the first ENaC inhibitor to demonstrate statistically significant efficacy in CF since the field largely collapsed ~10 years ago, succeeding where Vertex, Boehringer Ingelheim, AstraZeneca, and Novartis abandoned development
- •The drug targets a genuine unmet need: the ~10% of CF patients with mutations ineligible for CFTR modulator therapy, who currently lack disease-modifying treatment options
- •Next: Phase 2b dose-ranging trials, combination studies with CFTR modulators, and non-CF bronchiectasis indication will determine whether ETD001 can achieve clinically meaningful benefits and commercial viability in a small, genetically-defined patient population
Enterprise TherapeuticsVertex PharmaceuticalsParion SciencesETD001Alyftrek
→ Read original articleClinical Trials•Fierce Biotech•May 12, 2026
Blood-based approach could detect early heart, kidney disease, study finds
background ▾
- •Novel blood test detecting glycocalyx damage on red blood cells could enable non-invasive, scalable screening for early heart and kidney disease—addressing a major unmet need in preventative medicine
- •The biomarker approach may also serve as a rapid pharmacodynamic readout for drug efficacy, potentially accelerating development timelines for cardiovascular and renal therapeutics
Clinical Trials•Endpoints News•May 12, 2026
Flagship startup, Serif, says it has solved non-viral gene therapy in monkeys
background ▾
- •Serif Bio reports preclinical breakthrough in non-viral gene therapy in primates, addressing delivery and efficacy challenges that have historically limited this modality
- •Flagship Pioneering backing and startup status suggest well-capitalized entry into competitive gene therapy space, though clinical translation timeline and human data remain unknown
- •Success in non-viral approach could diversify gene therapy toolbox beyond viral vectors, but claims require validation through IND-enabling studies and early clinical data
Serif BiomedicinesFlagship Pioneering
→ Read original articleClinical Trials•Endpoints News•May 11, 2026
Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win
background ▾
- •Braveheart Bio's Hengrui-licensed cardiac drug achieved positive Phase 2 efficacy data, de-risking the program and supporting advancement toward late-stage development
- •This is the second clinical win for this therapy, suggesting consistent efficacy signals across trial populations and strengthening commercial prospects
- •Watch for: regulatory guidance meetings, Phase 3 initiation timeline, and competitive landscape shifts in the cardiac/heart muscle disease space
Braveheart BioJiangsu Hengrui Pharmaceuticals
→ Read original article